Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com
Repligen Corporation (RGEN) stock has hit a new 52-week high of $176.52, reflecting a significant 1-year change of 36.68% and a market capitalization of $9.38 billion. This surge follows strong Q2 2026 earnings, where the company surpassed Wall Street expectations for both adjusted earnings per share and revenue, prompting an increased full-year outlook. Despite this, Canaccord Genuity has reiterated a "Hold" rating with a price target of $145.
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com
Repligen Corporation (RGEN) stock has reached a 52-week high of $176.52, reflecting a significant 36.68% increase over the past year. The company's market capitalization is $9.38 billion, and it has reported strong financial performance, including a 16.49% revenue growth and exceeding Wall Street's Q2 2026 earnings expectations. Despite some analyst opinions suggesting the stock is overvalued, the upward trend and revised earnings forecasts indicate positive investor sentiment and robust operational health for the biotechnology firm.
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN
Oppenheimer Asset Management Inc. has acquired a new stake of 46,326 shares, valued at approximately $6.3 million, in Repligen Corporation ($RGEN) during the second quarter. Repligen has received a consensus "Buy" rating from analysts with an average price target of $166.43, and the company recently surpassed quarterly earnings and revenue expectations. Institutional investors hold a significant 97.64% of Repligen's stock.
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, reporting a 3.1% beneficial ownership stake in Repligen Corp (RGEN), totaling 1,751,887 shares of common stock as of June 30, 2026. The filing indicates sole voting power over 1,744,549 shares and sole dispositive power over all 1,751,887 shares. T. Rowe Price explicitly states this ownership is 5% or less of the class and denies broader beneficial ownership beyond what is reported.
Repligen Corporation (RGEN) Stock Forecasts
Argus has raised its target price for Repligen Corporation (RGEN) to $173.00. Repligen, a global life sciences company, specializes in developing bioprocessing equipment and supplies for manufacturing biologic drugs. The current stock price for RGEN is $167.49.
Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN
Wasatch Advisors LP has significantly increased its stake in Repligen Corporation (NASDAQ:RGEN) by 27.9%, purchasing an additional 346,720 shares, bringing its total holdings to 1.59 million shares valued at approximately $217 million. This makes Repligen the 19th largest holding for Wasatch Advisors, representing 1.4% of its investment portfolio. Other institutional investors have also adjusted their positions in Repligen, while analysts maintain a "Moderate Buy" rating with a consensus price target of $166.43, noting the company's recent earnings beat and reaffirmed guidance.
Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN
Assenagon Asset Management S.A. has acquired 70,995 new shares of Repligen Corporation (NASDAQ:RGEN) valued at approximately $9.7 million, making them a 0.13% owner of the biotechnology company. Repligen recently surpassed its quarterly earnings and revenue expectations, reporting $0.54 EPS against a $0.45 consensus, with revenue up 11.9% year-over-year. The company maintains a "Moderate Buy" consensus rating from analysts, with shares trading near their 52-week high and a target price of $166.43.
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages
Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $166.43. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.54 EPS and $204.13 million in revenue, an 11.9% year-over-year increase. Despite a CFO selling shares, institutional investors hold a significant 97.64% stake in the biopharmaceutical company.
Repligen Corporation (RGEN) Stock Analysis: A Healthcare Standout with 13.3% Potential Upside
Repligen Corporation (RGEN) is analyzed as a strong player in the healthcare sector, specifically medical instruments and supplies, with a current market cap of $9.25 billion and a potential upside of 13.3% according to analysts. The company shows promising revenue growth, positive analyst sentiment with strong buy ratings, and bullish technical indicators. Repligen's innovative bioprocessing technologies and strategic partnerships position it for sustainable growth in the life sciences and biopharmaceutical sectors.
Repligen (RGEN) Could Be 10% Below Fair Value On Mixed Q2 Earnings
Repligen (RGEN) recently reported mixed Q2 2026 earnings, showing higher revenue but lower net income and EPS year-over-year. Despite this, the stock has seen strong recent momentum, with a 90-day return of 41.4% and a 1-year return of 47.09%, positioning it about 10% below its fair value of $182 per share according to a detailed valuation narrative. However, while discounted based on DCF, the company trades at a premium P/S ratio compared to its industry and peers, indicating potential risks if growth falters.
Is Repligen’s (RGEN) Rising Revenue But Softer Earnings Rewriting Its Profitability Story?
Repligen Corporation (RGEN) reported rising revenue in Q2 2026, reaching US$204.13 million, but net income and earnings per share fell compared to the previous year. This performance highlights a conflict between increased demand and pressure on profitability due to the company's cost structure and product mix. Investors are advised to consider the impact of margin pressure and product mix shifts on Repligen's ability to convert revenue growth into sustainable earnings.
California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN
The California State Teachers Retirement System increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.1% in the first quarter, now holding 61,860 shares valued at $7.3 million. Repligen exceeded analyst expectations with quarterly revenue of $204.13 million and earnings of $0.54 per share, and institutional investors own 97.64% of the company. Despite some analysts lowering price targets, the stock maintains a consensus "Moderate Buy" rating with an average target price of $166.43.
Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN
Moody National Bank Trust Division has acquired a new stake in Repligen Corporation (NASDAQ:RGEN), purchasing 17,728 shares valued at approximately $2.42 million. This investment comes as institutional investors collectively own 97.64% of the biotechnology company. Repligen recently reported strong quarterly earnings, exceeding analyst expectations with $0.54 EPS and $204.13 million in revenue.
Repligen Corporation (BLFS) sets cash and stock terms for BioLife Solutions buyout
Repligen Corporation has announced an agreement to acquire BioLife Solutions for a combination of cash and stock. BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share. The transaction, described as a strategic combination in the cell therapy market, is anticipated to close in the fourth quarter of 2026, pending regulatory and BioLife stockholder approvals.
BioLife Solutions (NASDAQ: BLFS) shares Repligen merger video with staff
BioLife Solutions (NASDAQ: BLFS) has informed its employees about its pending merger with Repligen Corporation, distributing an internal email with a video from Repligen's CEO. The video introduces Repligen and discusses the anticipated benefits of the combination, particularly growth opportunities in the cell therapy market. The merger is subject to regulatory clearances and BioLife stockholder approval and is expected to close in the fourth quarter of the current year.
How Repligen Corporation (RGEN) Affects Rotational Strategy Timing
This article analyzes Repligen Corporation (RGEN) using AI models to offer trading strategies. It highlights a strong near-term sentiment with a neutral mid- and long-term outlook, identifying an exceptional risk-reward setup. The analysis provides specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies.
Repligen Number of Employees 2026 | Employee Count & Headcount Data
Repligen Corp. (NASDAQ: RGEN) had approximately 1,994 employees worldwide as of March 2026, representing a 1.7% growth from 2023. The company is actively hiring, though job postings declined by 16.1% in 2026. The majority of its workforce is located in the United States, and the average employee salary is $97,591.
Why Repligen (RGEN) Is Up 6.9% After Mixed Q2 2026 Results With Higher Revenue And Lower EPS
Repligen (RGEN) stock increased by 6.9% despite mixed Q2 2026 results which showed higher revenue but lower EPS. The company reported revenue of US$204.13 million, up from US$182.37 million year-over-year, but net income and diluted EPS declined. Analysts have revised earnings estimates higher, maintaining a positive long-term view despite near-term margin pressure and recent index removals impacting sentiment.
Why Repligen (RGEN) Is Up 6.9% After Mixed Q2 2026 Results With Higher Revenue And Lower EPS
Repligen Corporation (RGEN) reported mixed Q2 2026 results, with revenue increasing to US$204.13 million from US$182.37 million year-over-year, but net income and diluted EPS falling to US$5.01 million and US$0.09 respectively. Despite the decline in profitability, analysts have raised earnings estimates and maintained a positive outlook on the company's long-term earnings potential, leading to a 6.9% stock price increase. The article discusses how these results and recent index removals affect the investment narrative, emphasizing the importance of monitoring profit margin recovery.
Repligen Corp (RGEN) Institutional Confidence
Repligen Corp (RGEN) has an institutional confidence score of 10.00, placing it first in its industry. Institutional shareholding increased by 3.23% quarter-over-quarter, with Lee Ainslie being the largest shareholder. The article lists the top institutional shareholders and their recent activity.
Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G
Vanguard Capital Management has disclosed a 5% beneficial ownership stake in Repligen Corp (RGEN) through a Schedule 13G filing. This represents 2,825,579 shares of common stock, with Vanguard holding sole voting power over 414,408 shares and sole dispositive power over all 2,825,579 shares. The filing indicates these holdings are across Vanguard Capital Management LLC and its affiliated entities, including various Vanguard funds and managed accounts, and no single other person has an interest exceeding 5%.
Repligen (RGEN) Stock Faces A Margin Puzzle After Revenue Growth
Repligen (RGEN) recently reported Q2 2026 earnings with revenue growth and expanded adjusted gross and operating margins, despite a slip in net income. The article discusses the bull and bear cases for the stock, focusing on the company's shift towards recurring revenue and its struggle with filtration issues and cyclicality. Investors are evaluating whether the improved margin story justifies its premium valuation.
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup
Repligen (NASDAQ:RGEN) is highlighted as a compelling stock due to its strong fundamental growth, including significant revenue and EPS increases, combined with a promising technical breakout setup. The company shows an impressive growth rating with accelerating EPS expectations, despite an elevated valuation. Technically, RGEN is consolidating near resistance, and a breakout could lead to further price appreciation.
Repligen Corp Q2 2026: Revenue $204.1M, EPS $0.09— 10-Q Summary
Repligen Corp (RGEN) reported its second-quarter 2026 results, with revenue increasing by 11.9% year-over-year to $204.1 million. Despite the revenue growth, net income declined to $5 million, and diluted earnings per share fell to $0.09 from $0.26 in the prior-year quarter. The company also announced strategic moves including the acquisition of 908 Devices PAT Portfolio and a merger agreement to acquire BioLife for approximately $1.5 billion to expand its cell therapy offerings.
BioLife $1.5B buyout to expand Repligen Corporation (NASDAQ: RGEN) platform
Repligen Corporation reported strong Q2 2026 revenue of $204.1 million, an 11.9% increase from Q2 2025, with first-half revenue reaching $398.4 million. The company announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to expand its cell therapy capabilities. This acquisition, expected to close in Q4 2026, will involve a mix of cash and stock for BioLife stockholders, and is part of Repligen's strategy to enhance its bioprocessing platform.
Why Repligen (RGEN) Stock Is Up Today
Shares of Repligen Corporation (NASDAQ: RGEN) rose significantly after the biopharma manufacturing company reported strong second-quarter results, beating analyst expectations for both adjusted earnings and revenue. The company also raised its full-year guidance, signaling confidence in its continued performance. This positive news contrasts with a recent report where Repligen's stock saw a drop due to concerns over a rising number of uninsured patients, which could impact the broader healthcare industry.
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier
Repligen is highlighted as a leading provider of bioprocessing solutions for biologic drug manufacturers. The company offers a range of advanced systems including filtration, fluid management, chromatography columns, and process analytics. Despite its relatively small size, Repligen is noted for its innovation and record of launching new products with limited competition.
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Repligen (RGEN) reported strong second-quarter 202
Canaccord reiterates Hold on Repligen stock, keeps $145 target
Canaccord Genuity has reiterated a Hold rating on Repligen Corp. (NASDAQ:RGEN) and maintained its $145 price target, believing the shares are fairly valued. The bioprocessing company exceeded analyst expectations for its second-quarter 2026 results, reporting strong revenue growth across all franchises and raising its 2026 revenue guidance. These positive developments reflect the company's strong performance and confidence in future growth.
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase. The company also announced a definitive agreement to acquire BioLife Solutions, aiming to enhance its cell therapy leadership. Following these positive outcomes, Repligen raised its full-year 2026 financial guidance for organic revenue growth and adjusted EPS.
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase. The company also announced raising its full-year 2026 financial guidance, anticipating organic revenue growth of 10.5%-13.5% and adjusted EPS of $2.03-$2.09. Additionally, Repligen highlighted its definitive agreement to acquire BioLife Solutions, aiming to strengthen its position in cell therapy.
Repligen Corporation Stock 12‑Month Price Target Raised to $180.33, Implies 38% Upside
Analysts have raised Repligen Corporation's average 12-month price target to $180.33, up from $176.28. This new target suggests a potential upside of approximately 38% from its July 27 closing price. The consensus rating for RGEN remains a "Buy" among 22 analysts.
Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...
Repligen Corp (RGEN) reported strong Q2 2026 results including 12% reported revenue growth and a 460 basis point expansion in adjusted operating margin. The company raised its full-year guidance for organic revenue growth and adjusted EPS, driven by significant growth in its Proteins and Analytics segments, and strong performance in the Asia Pacific region. While capital equipment sales were muted, there was a sequential pickup in orders, indicating potential for strong performance in 2027.
Repligen Stock Rises As $1.5B BioLife Deal Targets EPS Boost
Repligen Corporation's stock rose significantly after announcing a $1.5 billion cash-and-stock deal to acquire BioLife Solutions. This acquisition aims to boost Repligen's EPS, adjusted margins, and revenue growth by expanding its bioprocessing footprint into the rapidly growing cell and gene therapy market with BioLife's high-margin products. The deal is expected to close in Q4, with management projecting substantial cost synergies and notable EPS accretion in the first two years post-acquisition.
Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat
Repligen (NASDAQ:RGEN) reported a significant earnings beat for Q2 2026, with non-GAAP EPS of $0.54 against an analyst consensus of $0.46, despite revenue being marginally below expectations. The stock surged over 75% in pre-market trading, recouping recent losses, as investors prioritized profitability improvements. The company also reaffirmed its full-year 2026 guidance, highlighting its strong position in bioprocessing technologies.
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript
Repligen Corp announced strong Q2 2026 earnings, with 12% reported growth and 13% organic growth, leading to a raised full-year guidance for organic revenue and adjusted EPS. The company saw robust performance in proteins and analytics, with significant growth in APAC and emerging biotech. Repligen also highlighted the strategic acquisition of BioLife, which is expected to fast-track its cell therapy strategy and be financially accretive, contributing to future growth and margin expansion.
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance
Repligen Corporation announced strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase and 13% organic growth. Due to this performance and continued order momentum, the company has raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted earnings per share guidance to $2.03-$2.09. Additionally, Repligen highlighted a definitive agreement to acquire BioLife Solutions, a strategic move expected to enhance its position in the cell therapy market.
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance
Repligen reported strong second-quarter 2026 results with revenue of $204.1 million, a 12% year-over-year increase, and adjusted diluted EPS of $0.54. The company has raised its full-year 2026 guidance for organic revenue growth and adjusted diluted EPS, driven by continued order momentum and portfolio diversification. Key highlights include the acquisition of BioLife Solutions and the opening of a new Training & Innovation Center.
Repligen to Acquire BioLife Solutions, Enhancing Cell Therapy Capabilities
Repligen Corporation announced its intent to acquire BioLife Solutions for approximately $1.5 billion, a strategic move aimed at strengthening Repligen's position in the rapidly expanding cell therapy market. The acquisition, valued at $31.00 per share, combines 64% Repligen stock and 36% cash, with the deal expected to close in Q4 2026. This merger is projected to boost Repligen's offerings, increase top-line growth, and yield significant synergies from operational efficiencies.
Repligen Corp (RGEN) Cash Flow
This article provides a detailed cash flow statement for Repligen Corp (RGEN), including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and provides key figures for RGEN, such as operating cash flow, capital expenditures, and free cash flow in recent periods. The data helps evaluate the company's financial health and stability.
Repligen (RGEN) Q2 Earnings: What To Expect
Repligen (RGEN) is set to report its Q2 earnings this Tuesday morning. Analysts expect the biopharma manufacturing company's revenue to grow 10.7% year over year, a slowdown from the previous year. The company beat revenue and EPS expectations last quarter, and analysts have generally reconfirmed their estimates for the upcoming report.
Repligen Corporation Revenue Breakdown – NASDAQ:RGEN
This article details Repligen Corporation's revenue breakdown. Last year, the company generated $738.26 million USD, with its Filtration segment being the top performer at $402.79 million USD. North America was the largest regional contributor, accounting for $361.75 million USD.
Repligen Corp|Price:131.970|Chg%:-5.630
This article provides a company profile for Repligen Corporation (RGEN), a global life sciences company specializing in bioprocessing technologies. It details the company's focus areas, product portfolio, and key financial information. The article also lists company executives, their shareholdings, and institutional ownership data for RGEN.
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Repligen Corp (RGEN) by business segment and by region. For FY2025, filtration products were the largest segment, contributing 54.58% of revenue, while North America was the largest regional market at 49.00%. The data highlights the company's key revenue drivers across its diverse product lines and geographical presence.
Repligen Corporation (RGEN) stock price, news, quote and history
This page provides a comprehensive overview of Repligen Corporation (RGEN) stock, including its current price, news, historical data, and financial analysis. It details the company's bioprocessing technologies and systems, product offerings, and recent financial performance, alongside analyst insights and comparisons with similar companies.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Repligen Corporation announced an agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to strengthen its position in the rapidly growing cell therapy market. This acquisition is expected to complement Repligen's existing solutions, add a high-margin consumables business, and be accretive to revenue growth, adjusted margins, and EPS. The deal is projected to close in Q4 2026, with anticipated cost synergies and funding from Repligen's existing cash reserves.
Canaccord reiterates Hold on Repligen stock after BioLife deal
Canaccord Genuity has reiterated a Hold rating on Repligen Corp. with a $145.00 price target following Repligen's acquisition of BioLife Solutions for approximately $1.5 billion. While the acquisition is expected to be accretive to Repligen's financials and expand its presence in new modalities, Canaccord will remain on the sidelines until the company executes on merger synergies and reaccelerates momentum. The article also notes recent positive analyst coverage and Q1 2026 financial results for Repligen.
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal
Repligen Corp. announced its plan to acquire BioLife Solutions Inc. for approximately $1.5 billion. The deal, comprising 64% Repligen common stock and 36% cash, aims to expand Repligen’s presence in the growing cell-therapy market and broaden its product offerings. Both companies' directors have unanimously approved the transaction, which is expected to close in the fourth quarter of 2026.
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Repligen Corp announced its acquisition of BioLife Solutions in a $1.5 billion cash-and-stock deal, aiming to enhance its presence in the rapidly expanding cell therapy market. This acquisition grants Repligen access to BioLife's cell preservation technology, processing tools, and high-margin consumables business. The deal, unanimously approved by both boards, is anticipated to close in Q4 2026 and is expected to boost Repligen's earnings while generating at least $20 million in first-year savings.
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition
Repligen, a life sciences company based in Waltham, Massachusetts, is set to acquire Washington-based BioLife Solutions Inc. for $1.5 billion. The acquisition, a mix of cash and stock, aims to expand Repligen's capabilities in the cell therapy market by integrating BioLife Solutions' cell processing tools. This strategic move highlights Repligen's focus on growth and diversification within the rapidly developing life sciences sector.
